Abstract Objective Thymoma‐associated myasthenia gravis ( TAMG ) is a type of myasthenia gravis (MG) that has a higher likelihood of worsening in comparison with non‐ TAMG , and MG symptoms often worsen after thymectomy. We measured peripheral T/B lymphocyte subsets before and after thymectomy in TAMG patients , and investigated the relationships with the occurrence of postoperative exacerbation of MG symptoms. Methods Participants were 10 TAMG patients, 40 healthy controls and five other surgical control patients. Peripheral lymphocyte subsets were measured using FACS ‐Canto flow cytometry before, and 1, 7, and 28 days after thymectomy in the TAMG , and before and 7 days after thymectomy in the other surgical control patients. Results Natural killer cells modestly decreased, and plasmablasts increased significantly ( P = 0.005) after 7 days postoperatively in comparison with preoperative values. Conversely, no obvious changes were observed in plasmablasts or natural killer cells in T/B lymphocyte subsets. From evaluation of postoperative clinical course and plasmablasts, exacerbation of MG symptoms was observed between 2 and 3 weeks after thymectomy in five of 10 patients (50%) of TAMG . In these five patients, plasmablasts markedly increased after thymectomy in three patients, among whom two patients had originally shown high plasmablast levels before thymectomy. There were also two patients who exacerbated without changes in plasmablast levels. Conclusions In patients with exacerbation of neurological symptoms after thymectomy for TAMG , the plasmablast levels were originally high and/or became high postoperatively. Thus, elevated plasmablast levels could potentially be predictive of postoperative exacerbation of MG .
The Brief International Cognitive Assessment for MS (BICAMS) is a practical battery for measuring cognitive function in multiple sclerosis (MS).We aimed to validate a Japanese version of the BICAMS in patients with MS and healthy controls.The Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-Second Edition (CVLT2) and the Brief Visuospatial Memory Test Revised (BVMTR) were administered to 156 patients with MS and 126 healthy controls (HCs). The BICAMS was re-administered in a subset of 27 MS patients and 30 HCs.The mean (±SD) raw scores in the MS and HC groups were as follows: SDMT: MS 47.9 ± 14.0, HC 61.0 ± 9.5; CVLT2: MS 48.6 ± 12.6, HC 55.7 ± 10.5; BVMTR: MS 23.5 ± 8.4, HC 28.3 ± 5.4, respectively, and significant differences were found between the two groups on all tests (p < 0.0001). Cohen's d values were 1.07, 0.60, and 0.67 in SDMT, CVLT2, and BVMTR, respectively. The test-retest reliability coefficients for each test were as follows: SDMT: r = 0.93; CVLT2: r = 0.82; and BVMTR: r = 0.77 (p < 0.0001).This study provides results that support the reliability and validity of the BICAMS in Japan.
